In 2004, Gunn added a regular segment on biotechnology, BioTech Nation. It has emerged as the only regular weekly mainstream programming on biotech on the national and international scene, and features interviews with biotech leaders. In its regular feature: “BioIssue of the Week”, Gunn discusses the breaking news of the day with award-winning science journalist, David Ewing Duncan.
In the U.S., Tech Nation can be heard four times each weekend on the National Public Radio website’s 24-hour Program Stream (npr.org). It airs on nearly 200 public radio stations, with multiple airtimes on the NPR Channels on XM-Sirius Satellite Radio. Globally, Tech Nation is aired three times weekly on the NPR Channels of Sirius Internet Radio and airs 25 weekly to 177 countries via Armed Forces Radio International. Tech Nation podcasts remain permanently archived on the Internet, enabling anyone, anywhere to listen to these materials on demand.
-
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation...Moira speaks with Neil Klompas of Augurex Life Sciences, about a new diagnostic for chronic, long-term back pain that pinpoints a form of arthritis. On average, patients with this condition could go 7-10 years without a diagnosis, having to first eliminate everything else with an odyssey of tests. Now, a simple blood test could be the answer.For more information about BioTech Nation and the companies featured here, visit: TechNation.com
-
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation, Moira speaks with Dr. Barry Quart, CEO of Connect Biopharma, about a new fast-acting treatment for inflammatory conditions like Asthma, COPD, and Eczema. Often, these conditions can be managed with anti-inflammatory therapeutics like Dupixent, but even then, sudden and painful flare-ups can occur. We take a closer look at a new anti-inflammatory in late-stage development which starts working quickly, much needed when those flare-ups develop. For more information about BioTech Nation and the companies featured here, visit: TechNation.com
-
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation...Dr. Harry Selker & Dr. Atul Deshpande of Immediate Therapeutics speak with Moira about a new treatment that could be administered to heart attack patients right away...potentially before they even arrive at the hospital. Already successfully tested in Phase 2, it’s ready to go into final pivotal trials in Ambulances and Emergency Rooms.For more information about BioTech Nation and the companies featured here, visit: TechNation.com
-
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation...Ever wonder what makes opioids so addictive? Moira speaks with Ketan Mehta, Founder and CEO of Tris Pharma, about opioid-induced euphoria...and an opioid that's actually meant to suppress this response. For more information about BioTech Nation and the companies featured here, visit: TechNation.com
-
This is the 2026 BioTech Nation "5": Five Companies Ready to Make a Difference. We're highlighting 5 biotech companies with a special release of interviews in time for the 44th Annual J.P. Morgan Healthcare Conference right here in San Francisco. Hear all 5 interviews at https://www.biotechnation.com/jpm-2026-btn-5On this episode of BioTech Nation: Can cancer cells be turned against themselves? Moira speaks with Cyriac Roeding and Dr. David Suhy, Co-Founders of Earli, about an innovative new approach to treating solid tumor cancer. They discuss their effort to turn the cancer cells inside solid tumors into factories that produce their own cancer-fighting therapeutic.For more information about BioTech Nation and the companies featured here, visit: TechNation.com
-
Decoding Diseases of Aging...Dr. Martin Borch Jensen and Dr. Francisco LePort, Gordian BiotechnologyThis week on Biotech Nation, Dr. Martin Borch Jensen and Dr. Francisco LePort from Gordian Biotechnology share a bold new approach to fighting diseases of aging before they take hold. Instead of testing one drug at a time, their technology allows scientists to test hundreds of potential treatments at once, making drug discovery faster and more precise. This could change how we treat conditions like arthritis, heart failure, and fatty liver disease.
-
This week on BioTech Nation, we explore what happens when your immune system overreacts. Professor Niels Riedemann, CEO of InflaRx, explains how the body’s defense system can sometimes cause more harm than good, leading to serious conditions like rheumatoid arthritis, severe COVID-19, and lung failure. Learn how InflaRx is developing treatments to calm the immune system and why their breakthrough drug is getting attention from U.S. health agencies.
-
This week on Biotech Nation, Dr. Ari Azhir, Founder and CEO of Neuvivo, shares the incredible journey of an ALS drug that was once abandoned, but is now making its way toward FDA approval. After two failed phase two trials, the drug was left behind until Dr. Azhir and her team discovered a crucial mistake in the trial data. Now with new insights and groundbreaking survival results, Neuvivo is giving hope to ALS patients and exploring its potential for other neurodegenerative diseases like Huntington’s and Alzheimer’s.
-
This week on BioTech Nation, Bruin Biometrics CEO Martin Burns talks about a new diagnostic tool being used to detect and prevent potentially fatal bedsores in their earliest stages.
-
For years, we've all turned to Google to self-diagnose every cough, rash, and weird pain. Dr. Daniel Kraft says the shift is happening, from Dr. Google to Dr. ChatGPT.